Beyond Genomics: How New Biological Maps Are Transforming Drug Discovery

Genomics transformed precision medicine, but genes alone cannot capture the complex interactions that shape disease. A more complete biological map is emerging through multi-omics, advanced biomarkers, AI, machine learning, and high-dimensional data, giving researchers new ways to understand disease biology and make more informed drug discovery decisions.
Explore how PheWAS and multi-omics can reveal disease pathways and therapeutic targets that traditional approaches may miss, and how a deeper understanding of tau biology is helping researchers distinguish neurodegenerative disease subtypes, improve patient stratification, and guide biomarker-driven development. The collection also examines how AI and metabolomics are opening previously inaccessible areas of natural-product chemistry and enabling target-agnostic approaches to discovery.
Together, these advances point toward a new era of precision medicine built on understanding interconnected biological systems rather than isolated genes or pathways. See how researchers are translating richer biological data into better targets, biomarkers, development strategies, and ultimately more precise therapies.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.